Heat Biologics Company Profile (NASDAQ:HTBX)

About Heat Biologics (NASDAQ:HTBX)

Heat Biologics logoHeat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. It is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:HTBX
  • CUSIP: N/A
  • Web: www.heatbio.com
Capitalization:
  • Market Cap: $23.62 million
  • Outstanding Shares: 35,788,000
Average Prices:
  • 50 Day Moving Avg: $0.62
  • 200 Day Moving Avg: $0.64
  • 52 Week Range: $0.46 - $3.35
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.74
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $777,132.00
  • Price / Sales: 29.01
  • Book Value: $0.28 per share
  • Price / Book: 2.25
Profitability:
  • EBITDA: ($11,530,000.00)
  • Net Margins: -1,479.67%
  • Return on Equity: -148.01%
  • Return on Assets: -96.31%
Debt:
  • Current Ratio: 2.77%
  • Quick Ratio: 2.77%
Misc:
  • Average Volume: 420,123 shs.
  • Beta: 0.83
  • Short Ratio: 7.92
 

Frequently Asked Questions for Heat Biologics (NASDAQ:HTBX)

What is Heat Biologics' stock symbol?

Heat Biologics trades on the NASDAQ under the ticker symbol "HTBX."

How were Heat Biologics' earnings last quarter?

Heat Biologics, Inc. (NASDAQ:HTBX) posted its earnings results on Friday, March, 31st. The company reported ($0.12) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.07) by $0.05. The business had revenue of $0.12 million for the quarter, compared to analyst estimates of $0.13 million. Heat Biologics had a negative return on equity of 148.01% and a negative net margin of 1,479.67%. View Heat Biologics' Earnings History.

Where is Heat Biologics' stock going? Where will Heat Biologics' stock price be in 2017?

3 equities research analysts have issued 12 month price objectives for Heat Biologics' shares. Their forecasts range from $2.00 to $2.25. On average, they expect Heat Biologics' share price to reach $2.13 in the next year. View Analyst Ratings for Heat Biologics.

Are investors shorting Heat Biologics?

Heat Biologics saw a drop in short interest during the month of September. As of September 29th, there was short interest totalling 1,429,337 shares, a drop of 33.8% from the September 15th total of 2,159,713 shares. Based on an average trading volume of 312,051 shares, the days-to-cover ratio is presently 4.6 days. Approximately 4.2% of the shares of the stock are short sold.

Who are some of Heat Biologics' key competitors?

Who are Heat Biologics' key executives?

Heat Biologics' management team includes the folowing people:

  • Jeffrey Alan Wolf J.D., Chairman of the Board, Chief Executive Officer
  • Timothy J. Creech, Chief Financial Officer
  • Jeff Tobin Hutchins Ph.D., Chief Operating Officer, Chief Scientific Officer
  • Ann A. Rosar, Vice President - Finance, Corporate Secretary
  • Anil K. Goyal Ph.D., Vice President - Business Development
  • John K. A. Prendergast Ph.D., Director
  • Louis C. Bock, Independent Director
  • Michael Kharitonov Ph.D., Independent Director
  • John P. Monahan Ph.D., Independent Director
  • Edward B. Smith III, Independent Director

How do I buy Heat Biologics stock?

Shares of Heat Biologics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Heat Biologics' stock price today?

One share of Heat Biologics stock can currently be purchased for approximately $0.63.


MarketBeat Community Rating for Heat Biologics (NASDAQ HTBX)
Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  152 (Vote Outperform)
Underperform Votes:  78 (Vote Underperform)
Total Votes:  230
MarketBeat's community ratings are surveys of what our community members think about Heat Biologics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Heat Biologics (NASDAQ:HTBX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $2.13 (237.30% upside)
Consensus Price Target History for Heat Biologics (NASDAQ:HTBX)
Price Target History for Heat Biologics (NASDAQ:HTBX)
Analysts' Ratings History for Heat Biologics (NASDAQ:HTBX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/12/2017Griffin SecuritiesInitiated CoverageBuy$2.25HighView Rating Details
7/4/2017Noble FinancialReiterated RatingBuyLowView Rating Details
12/8/2016Roth CapitalSet Price TargetBuy$2.00N/AView Rating Details
4/9/2016Cantor FitzgeraldReiterated RatingBuyN/AView Rating Details
2/21/2016HC WainwrightReiterated RatingBuy$13.00N/AView Rating Details
(Data available from 10/18/2015 forward)

Earnings

Earnings History for Heat Biologics (NASDAQ:HTBX)
Earnings by Quarter for Heat Biologics (NASDAQ:HTBX)
Earnings History by Quarter for Heat Biologics (NASDAQ HTBX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/31/2017Q4 2016($0.07)($0.12)$0.13 million$0.12 millionViewN/AView Earnings Details
11/10/2016Q3 2016($0.15)($0.08)$0.22 millionViewN/AView Earnings Details
8/15/2016Q2($0.27)($0.17)ViewN/AView Earnings Details
5/11/2016Q1($0.56)($0.50)ViewN/AView Earnings Details
2/18/2016Q4($0.64)($0.78)ViewN/AView Earnings Details
10/30/2015Q3($0.61)($0.62)ViewN/AView Earnings Details
8/13/2015Q2($0.47)($0.56)ViewN/AView Earnings Details
5/14/2015Q1($0.49)($0.57)ViewN/AView Earnings Details
4/16/2015($0.49)($0.56)ViewN/AView Earnings Details
3/27/2015Q4 2014($0.44)($0.56)ViewN/AView Earnings Details
11/14/2014Q314($0.35)($0.46)ViewN/AView Earnings Details
8/14/2014Q214($0.38)($0.44)ViewN/AView Earnings Details
5/13/2014Q1 2014($0.38)($0.36)ViewN/AView Earnings Details
4/1/2014($0.30)($0.55)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Heat Biologics (NASDAQ:HTBX)
2017 EPS Consensus Estimate: ($0.16)
2018 EPS Consensus Estimate: ($0.24)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20171($0.09)($0.09)($0.09)
Q4 20171($0.07)($0.07)($0.07)
Q1 20181($0.07)($0.07)($0.07)
Q2 20181($0.07)($0.07)($0.07)
Q3 20181($0.05)($0.05)($0.05)
Q4 20181($0.05)($0.05)($0.05)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Heat Biologics (NASDAQ:HTBX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Heat Biologics (NASDAQ:HTBX)
Insider Ownership Percentage: 8.70%
Institutional Ownership Percentage: 8.74%
Insider Trades by Quarter for Heat Biologics (NASDAQ:HTBX)
Institutional Ownership by Quarter for Heat Biologics (NASDAQ:HTBX)
Insider Trades by Quarter for Heat Biologics (NASDAQ:HTBX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/23/2016Michael KharitonovDirectorBuy900,000$0.75$675,000.00View SEC Filing  
5/19/2014Jeffrey Alan WolfCEOBuy2,500$4.13$10,325.00View SEC Filing  
5/16/2014Paul BelskyDirectorBuy2,500$4.11$10,275.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Heat Biologics (NASDAQ:HTBX)
Latest Headlines for Heat Biologics (NASDAQ:HTBX)
Source:
DateHeadline
streetinsider.com logoHeat Biologics (HTBX) Prices for Rights Offering - StreetInsider.com - StreetInsider.com
www.streetinsider.com - October 18 at 1:17 AM
streetinsider.com logoHeat Biologics (HTBX) Prices for Rights Offering
www.streetinsider.com - October 16 at 7:24 PM
finance.yahoo.com logoHeat Biologics Announces Pricing for Rights Offering to Stockholders and Participating Warrant Holders
finance.yahoo.com - October 16 at 7:24 PM
americanbankingnews.com logoHeat Biologics, Inc. (HTBX) Sees Significant Decrease in Short Interest
www.americanbankingnews.com - October 15 at 2:20 AM
finance.yahoo.com logoUPDATE: Heat Biologics to Present at the Upcoming BIO Investor Forum in San Francisco
finance.yahoo.com - October 13 at 12:16 AM
finance.yahoo.com logoBefore You Buy Heat Biologics Inc’s (HTBX), You Should Consider This
finance.yahoo.com - October 10 at 7:03 PM
businesswire.com logoSelexis SA and Pelican Therapeutics Sign Agreement to Advance ... - Business Wire (press release)
www.businesswire.com - October 4 at 3:32 PM
finance.yahoo.com logoSelexis SA and Pelican Therapeutics Sign Agreement to Advance Pelican’s Immunotherapy Clinical Programs
finance.yahoo.com - October 4 at 3:32 PM
streetinsider.com logoHeat Biologics (HTBX) Subsidiary Pelican Therapeutics Reports Manufacturing Agreement with KBI Biopharma to ... - StreetInsider.com
www.streetinsider.com - September 27 at 10:28 PM
americanbankingnews.com logoGriffin Securities Initiates Coverage on Heat Biologics, Inc. (HTBX)
www.americanbankingnews.com - September 18 at 12:16 AM
streetinsider.com logoHeat Biologics (HTBX) Plans Common Stock Rights Offering - StreetInsider.com
www.streetinsider.com - September 16 at 6:53 PM
finance.yahoo.com logoHeat Biologics Announces Common Stock Rights Offering in Form S-1 Filing
finance.yahoo.com - September 16 at 1:09 AM
americanbankingnews.com logoHeat Biologics, Inc. (HTBX) Forecasted to Earn Q3 2017 Earnings of ($0.09) Per Share
www.americanbankingnews.com - September 15 at 7:20 AM
streetinsider.com logoHeat Biologics (HTBX) Granted Type C Meeting with FDA to Discuss ... - StreetInsider.com
www.streetinsider.com - September 14 at 8:46 PM
finance.yahoo.com logoHeat Biologics Granted 180-day Extension by NASDAQ to Regain Compliance with Listing Requirements
finance.yahoo.com - September 14 at 8:46 PM
seekingalpha.com logoHeat Biologics (HTBX) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 14 at 6:09 AM
finance.yahoo.com logoHeat Biologics Granted Type C Meeting with FDA to Discuss Registrational Pathway for HS-110 in Combination with Opdivo(R) as a Treatment for Non-Small Cell Lung Cancer
finance.yahoo.com - September 13 at 12:06 AM
americanbankingnews.com logoAnalyzing Heat Biologics (HTBX) and its Competitors
www.americanbankingnews.com - September 12 at 12:30 PM
finance.yahoo.com logoHeat Biologics to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York
finance.yahoo.com - September 7 at 7:52 PM
finance.yahoo.com logoHeat Biologics Inc. Reports Second Quarter 2017 Results
finance.yahoo.com - August 14 at 7:55 PM
americanbankingnews.com logoHeat Biologics, Inc. (NASDAQ:HTBX) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - August 11 at 8:32 PM
finance.yahoo.com logoHeat Biologics Appoints Damien Hallet as Vice President of CMC Development
finance.yahoo.com - July 3 at 7:13 AM
finance.yahoo.com logoDr. Jeff Hutchins Appointed Chief Operating Officer for Heat Biologics
finance.yahoo.com - July 3 at 7:13 AM
finanznachrichten.de logoHeat Biologics, Inc.: Heat Biologics to Present at the 2017 Marcum Microcap Conference
www.finanznachrichten.de - June 7 at 5:20 PM
reuters.com logoBRIEF-Heat Biologics says net loss for Q1 of 2017 was $3.2 million
www.reuters.com - May 11 at 11:22 PM
streetinsider.com logoForm 8-K HEAT BIOLOGICS, INC. For: May 11
www.streetinsider.com - May 11 at 6:21 PM
biz.yahoo.com logoHEAT BIOLOGICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi
biz.yahoo.com - March 31 at 5:48 PM
biz.yahoo.com logoHEAT BIOLOGICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statemen
biz.yahoo.com - March 24 at 9:53 AM
biz.yahoo.com logoHEAT BIOLOGICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition
us.rd.yahoo.com - March 23 at 6:20 PM
us.rd.yahoo.com logoHeat Biologics Prices Offering of 5,000,000 Shares of Common Stock
us.rd.yahoo.com - March 23 at 6:20 PM
streetinsider.com logoHeat Biologics (HTBX) Plans Offering of Common Stock
www.streetinsider.com - March 22 at 5:56 PM
investopedia.com logoHeat Biologics Reports Positive NSCLC Drug Results (HTBX)
www.investopedia.com - March 21 at 5:46 PM
investopedia.com logoHeat Biologics Lung Cancer Drug Posts Good Results
www.investopedia.com - March 21 at 5:46 PM
investopedia.com logoHeat Biologics Lung Cancer Drug Posts Good Results
www.investopedia.com - March 21 at 5:46 PM
us.rd.yahoo.com logoHeat Biologics Reports Positive Interim Phase 2 Lung Cancer Results in Patients Treated with HS-110 in Combination with a Checkpoint Inhibitor
us.rd.yahoo.com - March 21 at 9:12 AM
bizjournals.com logoHeat Biologics faces threat of delisting – again
www.bizjournals.com - March 16 at 10:38 PM
biz.yahoo.com logoHEAT BIOLOGICS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standa
us.rd.yahoo.com - March 16 at 4:25 PM
us.rd.yahoo.com logoFlorida Department of Health Awards Three-Year Grant to Develop gp96-based Zika Vaccine
us.rd.yahoo.com - March 16 at 4:25 PM
investopedia.com logoHeat Biologics Lung Cancer Drug Combo Succeeds
www.investopedia.com - March 13 at 5:39 PM
streetinsider.com logoHeat Biologics (HTBX) Says it Met Efficacy Endpoint in Phase 1b Lung Cancer Trial
www.streetinsider.com - March 13 at 11:02 AM
us.rd.yahoo.com logoHeat Biologics Meets Efficacy Endpoint in its Phase 1b Lung Cancer Trial to Progress to Phase 2
us.rd.yahoo.com - March 13 at 11:02 AM
biz.yahoo.com logoHEAT BIOLOGICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - March 13 at 11:02 AM
bizjournals.com logoAustin cancer-fighting startup to rejoin public company it spun out from in 2012
www.bizjournals.com - March 9 at 3:50 PM
us.rd.yahoo.com logoHeat Biologics Announces Agreement to Acquire Pelican Therapeutics
us.rd.yahoo.com - March 8 at 6:34 PM
us.rd.yahoo.com logo7:02 am Heat Biologics to acquire 80% of Pelican Therapeutics for $500k in cash & about 1.32 mln shares of HTBX common stock
us.rd.yahoo.com - March 8 at 6:34 PM
bizjournals.com logoDurham outfit to acquire Texas company in a cash-stock deal
www.bizjournals.com - March 8 at 6:34 PM
bizjournals.com logoHeat Biologics offers further bladder cancer treatment outlook
www.bizjournals.com - February 22 at 12:46 PM
seekingalpha.com logoHeat Biologics (HTBX) Presents At 9th Annual Biotech Showcase 2017 Conference
seekingalpha.com - January 12 at 6:16 PM
biz.yahoo.com logoHEAT BIOLOGICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - January 6 at 6:23 PM
biz.yahoo.com logoHEAT BIOLOGICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Defini
biz.yahoo.com - January 4 at 4:49 PM

Social

Chart

Heat Biologics (HTBX) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.